» Articles » PMID: 10796394

Calcium and Vitamin D for Corticosteroid-induced Osteoporosis

Overview
Publisher Wiley
Date 2000 May 5
PMID 10796394
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To assess the effects of calcium and vitamin D compared to calcium alone or placebo in the prevention of bone loss in patients taking systemic corticosteroids.

Search Strategy: We searched the Cochrane Musculoskeletal trials register, Cochrane Controlled Trials Register, EMBASE and Medline up to 1996. We also conducted a hand search of abstracts from various scientific meetings and reference lists of selected trials.

Selection Criteria: All randomized trials comparing calcium and vitamin D to calcium alone or placebo in patients taking systemic corticosteroids.

Data Collection And Analysis: Data was abstracted from trials by two investigators. Methodological quality was assessed in a similar manner. Analysis was performed using fixed effects models.

Main Results: Five trials were included, with 274 patients. The analysis was performed at two years after starting calcium and vitamin D. There was a significant weighted mean difference (WMD) between treatment and control groups in lumbar (WMD 2.6 (95% CI 0.7, 4.5), and radial bone mineral density (WMD 2.5 (95% CI 0.6, 4.4). The other outcome measures (femoral neck bone mass, fracture incidence, biochemical markers of bone resorption) were not significantly different.

Reviewer's Conclusions: This meta-analysis demonstrated a clinically and statistically significant prevention of bone loss at the lumbar spine and forearm with vitamin D and calcium in corticosteroid treated patients. Because of low toxicity and cost all patients being started on corticosteroids should receive prophylactic therapy with calcium and vitamin D.

Citing Articles

A practical approach to positioning therapies in ulcerative colitis.

Yanofsky R, Rubin D J Can Assoc Gastroenterol. 2025; 8(Suppl 2):S6-S14.

PMID: 39990515 PMC: 11842905. DOI: 10.1093/jcag/gwae058.


Risk factors for fragility fractures in patients with immunobullous diseases on long-term systemic glucocorticoids.

May L, Chandran N Dermatol Reports. 2024; 16(3):9813.

PMID: 39635574 PMC: 11616581. DOI: 10.4081/dr.2024.9813.


Is endocrine surveillance important in the care of Duchenne Muscular Dystrophy? Results from a national survey to patients and families on endocrine complications.

Galetaki D, Szymczuk V, Shi M, Merchant N eNeurologicalSci. 2024; 36:100513.

PMID: 38989274 PMC: 11231648. DOI: 10.1016/j.ensci.2024.100513.


Ten tips on how to assess bone health in patients with chronic kidney disease.

Jorgensen H, Lloret M, Lalayiannis A, Shroff R, Evenepoel P Clin Kidney J. 2024; 17(5):sfae093.

PMID: 38817914 PMC: 11137676. DOI: 10.1093/ckj/sfae093.


Long non-coding RNA-NONMMMUT004552.2 regulates the unloading-induced bone loss through the miRNA-15b-5p/Syne1 in mice.

Zhang Z, Jing Y, Zhang A, Liu J, Yang H, Lou X NPJ Microgravity. 2024; 10(1):37.

PMID: 38521778 PMC: 10960867. DOI: 10.1038/s41526-024-00382-8.


References
1.
Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N . Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med. 1993; 328(24):1747-52. DOI: 10.1056/NEJM199306173282404. View

2.
Di Munno O, Beghe F, Favini P, Di Giuseppe P, Pontrandolfo A, Occhipinti G . Prevention of glucocorticoid-induced osteopenia: effect of oral 25-hydroxyvitamin D and calcium. Clin Rheumatol. 1989; 8(2):202-7. DOI: 10.1007/BF02030075. View

3.
Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds D, Gavaghan D . Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996; 17(1):1-12. DOI: 10.1016/0197-2456(95)00134-4. View

4.
Hahn T, Halstead L, Teitelbaum S, Hahn B . Altered mineral metabolism in glucocorticoid-induced osteopenia. Effect of 25-hydroxyvitamin D administration. J Clin Invest. 1979; 64(2):655-65. PMC: 372163. DOI: 10.1172/JCI109506. View

5.
Buckley L, Leib E, Cartularo K, Vacek P, Cooper S . Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1996; 125(12):961-8. DOI: 10.7326/0003-4819-125-12-199612150-00004. View